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Introduction {#sec005}
============

In 2012, the Centers for Disease Control and Prevention (CDC) released updated guidelines recommending one-time hepatitis C virus (HCV) screening for all individuals born between 1945 and 1965---the so-called "baby boomer" birth-cohort \[[@pone.0235778.ref001]\]. To reflect these guidelines, the state of Pennsylvania enacted the Hepatitis C Screening Act, which requires that "each individual born between the years of 1945 and 1965, who receives primary care services in an outpatient department of a hospital, health care facility or physician's office shall be offered a hepatitis C screening test" \[[@pone.0235778.ref002]\].

Prior to the initiation of these guidelines, waste in HCV screening has been a concern. Between 2006 and 2010, inappropriate duplicate antibody screening cost New York City an estimated \$14 million \[[@pone.0235778.ref003]\]. An evaluation of HCV screening in United States Veterans Affairs Hospitals demonstrated similar duplication patterns prior to the updated guidelines \[[@pone.0235778.ref004]\]. Despite the availability of previous testing in the electronic health record (EHR), forty percent of Veterans who had an initial positive screen had inappropriate duplicate testing \[[@pone.0235778.ref004]\]. In the era of broader HCV screening, the Centers for Medicare and Medicaid Services have called on providers to avoid inappropriate duplicate HCV screening so as to avoid waste and ensure coverage \[[@pone.0235778.ref005]\]. However, the burden of duplicate testing, both redundant and potentially appropriate, in baby boomers has yet to be described.

To address the CDC's 2012 recommendations, Drexel University College of Medicine (DUCOM) created the C for Cure program to spearhead HCV screening efforts in baby boomers at six of its urban primary care clinics. These clinics provide care for a medically-underserved patient population, many of whom require public insurance, with significant barriers to HCV screening \[[@pone.0235778.ref006], [@pone.0235778.ref007]\]. In this study we examine the results of the C for Cure's screening program, including overall testing rates, patterns of duplicate testing, and social determinants for overall and duplicate testing.

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

The study was conducted as a retrospective cohort study.

Study population {#sec008}
----------------

Birth-cohort data were extracted in deidentified datasets for all patients born between January 1, 1945 and December 31, 1965. To be considered eligible for the study, patients were required to be seen at least once at one of six DUCOM primary care sites between January 1, 2012 and July 31, 2017. This period was chosen given the implementation of updated CDC guidelines in 2012. Further, to be included in the analysis of a specific year, patients were required to be seen at least once during the year being evaluated. Patients were deemed ineligible for analysis for a given year if they were not seen during that year. Covariates of interest, linked as structured data to deidentified birth-cohort patients, were collected as a part of the data extraction from the DUCOM EHR. Covariates collected included birth year, gender, race, insurance status, practice location, and HCV screening and screening duplication results as defined below. Age was defined as patient age at the midpoint of the study.

Throughout the screening process, patients were followed by the C for Cure team, which included providers, nurses and patient navigators. The team provided patients with guidance regarding follow-up plans and treatment if warranted by the testing results. EHR decision support and provider education were included to help augment screening efforts at each of the six clinics.

Data source {#sec009}
-----------

All testing and demographic data were collected from the DUCOM outpatient EHR as deidentified data in the C for Cure database.

Definitions {#sec010}
-----------

HCV screening was defined as the completion of an HCV serum antibody test, regardless of the result. Duplicate testing was defined as repeat HCV antibody testing performed at any time point subsequent to the first recorded screening test. Inappropriate duplicate antibody screening was defined as antibody screening following an initial positive antibody screen. Potentially appropriate duplicate antibody screening was defined as repeat antibody testing for patients who had an initial negative HCV serum antibody screen. These tests were deemed potentially appropriate as these patients may have had a secondary ongoing risk---that is, a risk other than being birth-cohort patients---that may predispose them to seroconversion \[[@pone.0235778.ref008]\].

Statistical analysis {#sec011}
--------------------

Screening rates were calculated based upon eligible patients seen in a given year. Of those eligible patients, screening was assessed for both newly-screened and previously-screened individuals. Counts and simple percentages were performed for pooled testing and demographic data from all years of the study. Multivariate logistic regressions with clinics controlled as clusters were performed to examine the association of available demographic variables and the outcomes of having ever received HCV screening as well as having ever received duplicate HCV screening (alpha 0.05). All analyses were performed with Stata (Version 16.1, StataCorp, College Station, Texas).

Ethics {#sec012}
------

Approval of this project was provided by the Drexel University College of Medicine Institutional Review Board (Protocol Approval \# 1702005228). A waiver of consent and waiver of Health Insurance Portability and Accountability Act authorization were provided.

Results {#sec013}
=======

Baseline characteristics of the patient population eligible to be screened are summarized in [Table 1](#pone.0235778.t001){ref-type="table"}. 11,598 total eligible patients were evaluated for the study. Screening was largely uniform across age cohorts. Those screened were predominantly female, African American, and those with public insurance. Full data was available for all covariates with the exception of insurance, for which 272 patients had an unavailable insurances status.

10.1371/journal.pone.0235778.t001

###### Baseline characteristics of eligible patients.

![](pone.0235778.t001){#pone.0235778.t001g}

  Birth Cohort Patients Seen 2012--2017   Population Size N (% of Total)
  --------------------------------------- --------------------------------
  **Total**                               11,598 (100)
  **Gender**                              
   **Male**                               4627 (39.9)
   **Female**                             6971 (60.1)
  **Age cohort (years old)**              
   **50--54**                             3173 (27.3)
   **55--59**                             3263 (28.1)
   **60--64**                             2758 (23.7)
   **65--70**                             2404 (20.7)
  **Race**                                
   **White**                              4625 (39.9)
   **Black**                              5998 (51.7)
   **Asian**                              217 (1.9)
   **Others**                             758 (6.5)
  **Insurance**                           
   **Private**                            4039 (34.8)
   **Public**                             7287 (62.8)
   **Unavailable**                        272 (2.3)
  **Practices**                           
   **Clinic 1**                           2353 (20.2)
   **Clinic 2**                           2381 (20.5)
   **Clinic 3**                           2715 (23.4)
   **Clinic 4**                           2420 (20.8)
   **Clinic 5**                           987 (8.5)
   **Clinic 6**                           742 (6.4)

Cumulative screening rates for all clinical sites are described, by year, in [Fig 1](#pone.0235778.g001){ref-type="fig"}. Screening rates are characterized in the figure based upon the eligible pool of patients seen during a given year, including those who were newly-tested, previously-tested, or not tested. The cumulative HCV screening rate increased from 16% in 2012 to 82% in 2017. In 2012, previously-tested patients accounted for 11% of the total pool of eligible patients, while the newly-tested patients accounted for 5% of eligible patients. A gradual increase was seen in both the newly-tested and previously-tested patients. As of 2017, previously-tested patients made up 66% of the total eligible patients, while newly-tested patients made up 16% of the pool.

![Screening rates for eligible patients, by year.](pone.0235778.g001){#pone.0235778.g001}

Cumulative screening results and duplication patterns are described in [Fig 2](#pone.0235778.g002){ref-type="fig"}. During the study period, a total of 7927 screening tests were performed. Among the 6,717 patients screened, 1,208 (18%) had duplicate testing, only three of which had a third screening test. Of those who had duplicate testing, 170 (14%) had inappropriate duplicate antibody screening. 1,037 patients had duplicate screening that was potentially appropriate. Of those patients who had potentially appropriate duplicate testing, three seroconverted to a positive result on duplicate testing.

![Screening and duplication patterns.\
HCV, hepatitis C virus; Ab, antibody.](pone.0235778.g002){#pone.0235778.g002}

The outcomes of general and duplicate screening were analyzed through multivariate logistic regression, adjusted for clustering by clinic, to explore demographic determinants of each (Tables [2](#pone.0235778.t002){ref-type="table"} and [3](#pone.0235778.t003){ref-type="table"}). Prior to adjustment for clustering by clinic, race, type of insurance and clinic location were all associated with patients having ever been screened for HCV. After adjustment for clustering by clinic, African American and Asian patients had a significantly higher odds for ever being screened. Prior to adjustment for clustering, age, race, type of insurance and clinic location were all associated with duplicate testing. After adjustment, Asian patients and those with public insurance had a significantly higher odds of duplicate screening.

10.1371/journal.pone.0235778.t002

###### Multivariate logistic regression for ever receiving HCV screening, clustered by clinic.

![](pone.0235778.t002){#pone.0235778.t002g}

  Patients Seen From 2012--2017   HCV Ever- Tested N (%)   HCV Never- Tested N (%)   Odds Ratio (95% CI)   p-value
  ------------------------------- ------------------------ ------------------------- --------------------- ---------
  **Gender**                                                                                               
  ** Male**                       2706 (58.5)              1921 (41.5)               1                     
  ** Female**                     4011 (57.5)              2960 (42.5)               0.89 (0.67--1.18)     0.413
  **Birth Year**                                                                                           
  ** 1945--1955**                 2936 (56.9)              2226 (43.1)               1                     
  ** 1956--1965**                 3781 (58.7)              2655 (41.3)               1.06 (0.95--1.18)     0.285
  ** Race**                                                                                                
  ** White**                      2383 (51.5)              2242 (48.5)               1                     
  ** Black**                      3830 (63.9)              2168 (36.1)               1.71 (1.27--2.29)     \<0.001
  ** Asian**                      137 (63.1)               80 (36.9)                 1.68 (1.25--2.26)     \<0.001
  ** Others/unknown**             354 (47.7)               388 (52.3)                0.91 (0.65--1.28)     0.598
  **Insurance**                                                                                            
  ** Private**                    3776 (57.7)              2763 (42.3)               1                     
  ** Public**                     2856 (59.7)              1930 (40.3)               0.95 (0.77--1.18)     0.639

HCV, hepatitis C virus; CI, confidence interval

10.1371/journal.pone.0235778.t003

###### Multivariate logistic regression for duplicate HCV screening, clustered by clinic.

![](pone.0235778.t003){#pone.0235778.t003g}

  Patients Seen From 2012--2017   HCV-Tested More Than Once N (%)   HCV-Tested Once N (%)   Odds Ratio (95% CI)   p-value
  ------------------------------- --------------------------------- ----------------------- --------------------- ---------
  **Gender**                                                                                                      
  ** Male**                       456 (16.9)                        2250 (83.1)             1                     
  ** Female**                     751 (18.7)                        3620 (81.3)             1.06 (0.88--1.28)     0.510
  **Birth Year**                                                                                                  
  ** 1945--1955**                 485 (16.5)                        2451 (835)              1                     
  ** 1956--1965**                 772 (19.1)                        3059 (80.9)             1.15 (0.95--1.41)     0.158
  **Race**                                                                                                        
  ** White**                      259 (10.9)                        2124 (89.4)             1                     
  ** Black**                      862 (22.5)                        2968 (77.5)             1.62 (0.83--3.15)     0.157
  ** Asian**                      23 (16.8)                         114 (83.2)              2.17 (1.70--2.78)     \<0.001
  ** Others/unknown**             293 (82.8)                        293 (82.8)              1.71 (1.05--2.78)     0.030
  **Insurance**                                                                                                   
  ** Private**                    561 (14.9)                        3215 (85.1)             1                     
  ** Public**                     630 (22.1)                        2226 (77.9)             1.40 (1.01--1.93)     0.042

HCV, hepatitis C virus; CI, confidence interval

Discussion {#sec014}
==========

Despite expanded CDC guidelines for universal HCV screening, which now includes all adults \[[@pone.0235778.ref009]\], screening remains a challenge for higher risk patients with less access to care \[[@pone.0235778.ref007], [@pone.0235778.ref010]--[@pone.0235778.ref013]\]. Nonetheless, there have been successful screening programs described for such populations \[[@pone.0235778.ref014], [@pone.0235778.ref015]\]. Through the DUCOM C for Cure program, 58% of 11,598 baby boomer patients were screened for HCV during the study period. When we reviewed patients screened by year, the HCV screening rate increased from 16% screened previously or in 2012 to 82% in 2017. In 2017, not only had most patients in the practices already been tested, but almost half of the remaining untested patients were tested in that year.

Our findings illustrate that a high rate of HCV screening can be achieved with the implementation of a comprehensive program, despite our population's previously described barriers to care \[[@pone.0235778.ref006]\]. Previous data have supported the use of such programs. HCV continuum of care teams that include patient navigators improve screening and linkage-to-care \[[@pone.0235778.ref007], [@pone.0235778.ref016]--[@pone.0235778.ref018]\]. Furthermore, physician education and clinical support, including EHR-based tools, are likewise critical to improving testing rates \[[@pone.0235778.ref019]--[@pone.0235778.ref024]\].

Though the program was successful, we noted a significant amount of inappropriate duplicate HCV antibody screening, defined as repeat antibody testing in patients whose initial antibody tests were positive. Fourteen percent of all duplicate screening tests were inappropriate. For these patients, providers concerned about ongoing risk could have evaluated that risk of infection more appropriately through HCV viral load testing. The 1,037 remaining duplicates were potentially appropriate as the initial screening for these patients was negative. However, this study did not explore whether the potentially appropriate duplicate tests were truly appropriate re-screens or were the consequence of provider error. For example, patients with previously negative screens may have had duplicate testing for an appropriate reason, such as new or ongoing injection drug use. Alternatively, inappropriate duplicate antibody testing may have occurred if providers were unaware of previous screening or were unknowledgeable of the clinical appropriateness of re-screening.

Our analyses suggest that, among our population, there were significant social determinants for both having ever been tested as well as duplicate testing. For having ever been screened, race was a significant determinant of testing, particularly for African American and Asian patients. This may be reflective of more aggressive screening due to known racial disparities associated with HCV prevalence and related mortality \[[@pone.0235778.ref025], [@pone.0235778.ref026]\]. In regards to duplicate testing, race also appeared to remain a significant determinant for Asian patients, though not for African American patients. Further, having public insurance was significantly associated with duplication. This may be due to the City of Philadelphia's increased efforts at screening during the study period \[[@pone.0235778.ref002]\] as well as its liberalized coverage policies for HCV treatment in publicly insured patients \[[@pone.0235778.ref027], [@pone.0235778.ref028]\].

There are limitations to this study. The study only collected data on baby boomers without the collection of data on other comorbidities. This may be problematic for generalizability, particularly as it relates to baby boomers with more complex social and medical histories. For example, injection drug use remains prevalent in the United States and is an important risk for HCV acquisition \[[@pone.0235778.ref029], [@pone.0235778.ref030]\]. The CDC cites other risk factors for HCV infection, including HIV infection, incarceration, chronic hemodialysis, receipt of distant transfusions, and needlestick injuries \[[@pone.0235778.ref031]\]. Though not currently cited by the CDC, unprotected anal receptive sex among men who have sex with men has also been associated with an increased risk for HCV infection \[[@pone.0235778.ref032]\]. Future studies will need to address these risk factors and how they impact repeat HCV screening. Further, we hope to expand our evaluation beyond baby boomers to reflect universal adult screening recommendations as introduced by the CDC this year \[[@pone.0235778.ref009]\].

Conclusions {#sec015}
===========

In summary, this study describes the potential for inappropriate duplicate HCV antibody screening in the setting of updated CDC guidelines. For a large-scale program, such as C for Cure, inappropriate duplicate antibody testing may occur, which should prompt efforts to improve resource stewardship with directed repeat testing, using the appropriate modality, in patients with ongoing risk.

Supporting information {#sec016}
======================

###### 

(XLSX)

###### 

Click here for additional data file.
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We are resubmitting the manuscript previously titled "Screening Baby Boomers for Hepatitis C in Urban Primary Care Clinics: Does Duplicate Testing Make a Difference?" for further review. Reviewer comments have been considered and the paper has been edited to reflect the recommended revisions. We have itemized the comments and our responses to those comments below.

Editor comments:

Concern: "the aim of the study looks confusing. Reading the manuscript title, I expected that duplicate testing is a new strategy for screening of Hep C patients and the study is going to evaluate this strategy."

Response: We have changed the title to better reflect the aims of the study.

Concern: "Reading introduction and aim, I thought the duplicate testing is something unexpected in the primary care clinics but it is not elucidated why it cannot be prevented while they have EHR to document the HCV testing."

Response: The study's introduction and study aims have been re-written to clarify the goals of the paper. Previously described data regarding duplicate testing in the setting of available EHR records has been cited.

Concern: "In Data Availability, authors included \"Yes - all data are fully available without restriction\". Is there any dataset they want to share with the readers?"

Response: We will be sharing our dataset with readers with this submission.

Concern: "The Manuscript Title, PICO, aims, results and discussion should be synchronized to present the work done by the authors. As I included above, these are yet confusing, decrease the quality of evidence presentation. In introduction, there is little about what is the burden (economic, etc.) of HCV duplicate testing in a population with little ongoing risky behaviors. Why the duplicate testing is important? is it a problem? how can it impact the HCV screening? The aim should be expressed clearly considering the work done and the results will be presented."

Response: The study's introduction has been re-written to clarify the aims of the study. As the study was not a true interventional study (that is, there is no control group), it has been more correctly framed based on its observational aims. The edited version synchronizes the study's introduction and aims with the paper's results and discussion.

Concern: "In Abstract, \"aggressive screening efforts in high prevalence populations have led to significant costs despite a lack of clinical utility\". I am very confused with that statement. WHO recommends screening in populations with high prevalence of HCV (\>2% or \>5%) such as PWID, FSWs, etc."

Response: The abstract has been re-written to clarify the above as well as the goals of the paper.

Concern: "The methods, patient recruitment and documentation is not clear for the readers. As I get, this is a retrospective study using the data accumulated in EHR. I am not against using such data however, the reader needs to know what exactly happened. Was the screening started before 2012? how the baby boomers linked to diagnostics? what were the diagnostic services (methods, labs, etc)? how the results were documented in EHR? was there any counseling from Labs or clinics after testing?"

Response: The methods section now explains that screening rates were evaluated starting in 2012 as this was the year the new CDC guidelines were implemented. More details were provided regarding the data extraction as structured fields linked to baby boomer data. A statement was added regarding follow-up counseling provided by the C for Cure program.

Concern: "Were All the retestings duplicates? any triplicates?"

Response: There were only three triplicates noted in the study. This has been added to the results section.

Concern: "I am confused why the authors observed the retesting in those with negative HCV Ab as an appropriate phenomenon while these individuals mostly have no risk for transmission of HCV."

Response: This has been clarified in the Definitions sub-section of the Methods section with a citation to the AASLD-IDSA HCV guidelines.

Concern: "What was included in the data of Figure 1? The individuals?, the test results? or the visits in clinic?"

Response: The findings in Figure 1 have been clarified in the Results section.

Concern: "What was the number of individuals? number of tests? number of visits in clinic? these can be included in the results."

Response: The total number of patients and their characteristics are now described in Table 1 and paragraph 1 of the results section. The total number of tests performed is now included in the results section (line 117). We do not have the total number of clinic visits available.

Concern: "A Table presenting baseline characteristics of patients is needed."

Response: This table has been created and is now Table 1.

Concern: "In Figure 2, it is not clear what the duplicate tested branch is presenting? the initial testing results or the retesting results."

Response: The branchpoint has now been clarified that the results are of the retesting (duplicate) results.

Concern: "In Table 1, I guess public insurance should have OR more than 1."

Response: In the univariate analysis predicting ever tested (as shown in what was table 1 but is now table 2) with the same set of subjects as in the multivariate, public insurance does indeed have an OR greater than 1 (1.084) as would be expected since the percentage ever tested is greater in the public group than the private group. However, the analysis in table 2 is multivariate, adjusted for the other variables, and the direction of the association is reversed by the confounder correction. We redid the analyses with the same variables and coding to be sure there was not an accidental switch such that the wrong group was being counted as the reference in the model, and this is not the case. It appears that this small but statistically significant association is tied to other factors. Adding just race or just practice to the model, in addition to insurance type, reverses the direction of the association for insurance type. Adding sex or birth year high/low does not. So, it appears that the association of insurance type with ever tested is confounded by associations with race and practice, which makes sense.

Concern: "In Table 2, the second column can be used for presentation of HCV tested more than once and the third column for HCV tested once."

Response: We have switched the columns accordingly.

Concern: "95% CI of OR for gender in Table 2?"

Response: The CI of OR for gender has been included.

Reviewer \#1:

Concern: The authors provide more exact information regarding eligibility criteria and study type in a specific section in the methods part.

Response: We have clarified the inclusion criteria in the Study Population sub-section. We have added a statement about study design under the new sub-section, Study Design.

Concern: "The authors provide P-value for reported odds ration in the results part."

Response: P-values are included in our tables reporting odds ratios (now Tables 2 and 3).

Reviewer \#2:

Concern: "It is important to note that at the current time the recommendation is the screen all adults and all pregnant women, this manuscript should be updated to look at both baby boomer "duplicate screening" and potential problems with "duplicate screening" in all adults and all pregnant women"

Response: This dataset only includes data for baby boomers. We have now included the expansion of our study to all adults.

Concern: "There is a statement in the abstract that there is a lack of clinical utility for screening but this is not correct: utility and cost effectiveness has been proven please see AASLD and CDC guidelines, surveillance is recommended in at risk individuals, yes this is "duplicate" but it follows guidelines since at risk patients must be tested regularly and is not wasteful

There is a clear need for "duplicate testing" or "repeat testing" in at risk individuals who show evidence of high-risk behavior, How did the authors document that there was unnecessary duplicate testing, is there adequate documentation in the EMR that these are low risk individuals with no high-risk behavior?"

Response: In our limitations section we now address that our study is limited due to lack of knowledge regarding comorbidities that might increase risk. We have labeled patients who have had repeat antibody screening if their first screen is negative as "potentially appropriate" to address this concept within the given limitations of our data.

Concern: "AST and ALT are liver enzymes and or not liver function tests, were liver function test assessed or liver enzymes assessed?"

Response: We did not collect liver function tests as a component of our dataset. However, this is an excellent recommendation for data to be collected in future studies.

Reviewer \#3

Concern: "All the analyses should be adjusted for the cluster effect, as there are clusters (clinics) in the data.

Response: Adjusting for clusters in the multivariate analysis is a reasonable suggestion, but we do not believe it quite applies here. If we had randomly selected 5 units out of 20 and wanted to generalize to all 20, we would have to take into account the fact that the 5 might be atypical in some way. For example, if half the 20 units had a positive association between male gender and testing, while the other half had a negative association, we could easily by chance select 5 that showed the positive association, a different 5 that showed the negative, or 5 that were so mixed as to show no association. Adjustment for clustering would address that risk and give more generalizable results.

However, in this study we used essentially all of the units within the system. Our practices are not a sample from a larger citywide or nationwide set. They are a complete set within a single institution. Adjusting for clustering would not help with generalization to the system, since we included all the units (and all relevant patients within each). There is a question of generalization to the broader world, but that is not easily addressed given that this was a single institution study. If we had just taken one large unit from this study and analyzed that, there would be no cluster effect that we could control for, but exactly the same question of generalizability.

So, we believe that our analysis, with practices controlled as a fixed factor, and with recognition that the results of a single institutional study may have limited generalizability if there are important differences between systems, is an acceptable approach.

Concern: "A more rigorous conclusion is needed. The conclusion does not support the results. I see that part of duplicate testings were helpful. So, the authors should discuss if the rate of \"unnecessary\" duplicate testing is practically important."

Response: We edited the conclusion to more strongly follow the results. We clarified that providers concerned about ongoing risk in patients who might have been treated or spontaneously cleared might have evaluated that risk more appropriately through viral load testing.

Additional Requirements

Request: "When submitting your revision, we need you to address these additional requirements:

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and [http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf"](http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf”)

Response: We have reviewed the guidelines and have re-formatted our paper accordingly.

Request: "Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study and confirm that your named institutional review board or ethics committee specifically approved this study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission")."

Response: We have made the changes as requested.

Request: "Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate \"supporting information\" files"

Response: We have added our tables and figures to the manuscript.

Thank you for your consideration of this re-submission. We hope these revisions help to address your concerns. Please contact me with any further questions.

Sincerely,

Dagan Coppock, MD Thomas Jefferson University

Division of Infectious Diseases

\(c\) 203-915-7302

\(o\) 267-503-8845

\(f\) 215-503-3417

<dagan.coppock@jefferson.edu>

###### 

Submitted filename: Response to Reviewers.pdf

###### 

Click here for additional data file.

10.1371/journal.pone.0235778.r003

Decision Letter 1

Sharafi

Heidar

Academic Editor

© 2020 Heidar Sharafi

2020

Heidar Sharafi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

21 May 2020

PONE-D-20-03702R1
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PLOS ONE

Dear Dr. Coppock,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Authors addressed most of the comments and concerns correctly. There are few more comments by the reviewers should be considered by the authors before acceptance of their manuscript for publication in PLOS ONE.

Please submit your revised manuscript by Jul 05 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Heidar Sharafi

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Dear editor

I checked the revised version of the manuscript together with authors\' comments. All of my concerns have been resolved.

Best

Reviewer

Reviewer \#2: In the discussion, a small expansion/discussion of the limits of the study due to limited data on risk behaviour or co-morbidities that could lead to repeat testing (not duplicate testing {that implies that the second and third test were not necessary}).

Reviewer \#3: The authors have well addressed the comments.

However, for the concern I raised about cluster effect, further attention is needed. In studies where the data is grouped in the form of clusters (here, the clinics), the within-cluster correlations will shrink the total confidence intervals. So, the authors need to correct the confidence-intervals for the \"intra-class correlation coefficient\". Including all the clinics in your analysis, will not correct the \"cluster/design effect\", as this issue deals with the correlations that exist within your clusters (i.e., clinics).

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Robert Gish

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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20 Jun 2020

June 20, 2020

To the Editors of PLoS ONE:

We are resubmitting manuscript PONE-D-20-03702R1, titled "Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics," for further review. Reviewer comments have been considered and the paper has been edited to reflect the recommended revisions. We have itemized the comments and our responses to those comments below.

Reviewer \#1:

Comment: "I checked the revised version of the manuscript together with authors\' comments. All of my concerns have been resolved."

Response: We thank you for your comments.

Reviewer \#2:

Comment: "In the discussion, a small expansion/discussion of the limits of the study due to limited data on risk behaviour or co-morbidities that could lead to repeat testing (not duplicate testing {that implies that the second and third test were not necessary})."

Response: Thank you for the recommendation regarding the limitations. In the discussion section, we have expanded on the limits of the study due to our limited dataset. Further, your comments raise excellent points about our terminology. We have changed the language throughout the paper to clarify that duplicate testing may not be "unnecessary," particularly in the context of ongoing risk/co-morbidities. We have elucidated that repeat antibody screening in patients who already have a baseline positive antibody screen is an inappropriate means for assessing patients with ongoing risk and that viral load testing would be more appropriate.

Reviewer \#3:

Comment: "for the concern I raised about cluster effect, further attention is needed. In studies where the data is grouped in the form of clusters (here, the clinics), the within-cluster correlations will shrink the total confidence intervals. So, the authors need to correct the confidence-intervals for the \"intra-class correlation coefficient\". Including all the clinics in your analysis, will not correct the \"cluster/design effect\", as this issue deals with the correlations that exist within your clusters (i.e., clinics)."

Response: This was a very helpful recommendation. We re-performed our regressions, controlling for clustering by clinic. Our odds rations changed and our confidence intervals widened with a decrease in significance for specific variables. We have replaced our previous regression results with the clustered results and have changed our discussion accordingly.

Thank you for your consideration of this re-submission. We hope these revisions help to address your concerns. Please contact me with any further questions.

Sincerely,

Dagan Coppock, MD

Thomas Jefferson University

Division of Infectious Diseases

\(c\) 203-915-7302

\(o\) 267-503-8845

\(f\) 215-503-3417

<dagan.coppock@jefferson.edu>
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Dear Dr. Coppock,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Heidar Sharafi

Academic Editor

PLOS ONE
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PONE-D-20-03702R2

Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics

Dear Dr. Coppock:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Heidar Sharafi

Academic Editor

PLOS ONE
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